<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498275</url>
  </required_header>
  <id_info>
    <org_study_id>YP29018</org_study_id>
    <nct_id>NCT02498275</nct_id>
  </id_info>
  <brief_title>Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) in Chinese Healthy Volunteers and Chronic Hepatitis B Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is an exploratory study to characterize the ex vivo immune response to RO6871765 or&#xD;
      RO7011785 stimulation of peripheral blood mononuclear cells (PBMCs) extracted from healthy&#xD;
      volunteers and chronic hepatitis B (CHB) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation coefficients between baseline toll-like receptor 7 (TLR7) expression and ex vivo immune response upon stimulation of PBMCs with RO6871765 or RO7011785 (in terms of cytokine release and gene expression)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine/chemokine production</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction of interferon-responsive genes</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number or percentages of T-lymphocytes in healthy volunteers and subjects with CHB</measure>
    <time_frame>Screening Up to Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or percentages of B-lymphocytes in healthy volunteers and subjects with CHB</measure>
    <time_frame>Screening up to Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or percentages of natural killer (NK) -cells in healthy volunteers and subjects with CHB</measure>
    <time_frame>Screening up to Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or percentages of myeloid dendritic cells (mDCs) in healthy volunteers and subjects with CHB</measure>
    <time_frame>Screening up to Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or percentages of plasmacytoid dendritic cells (pDCs) in healthy volunteers and subjects with CHB</measure>
    <time_frame>Screening up to Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ex-vivo antiviral activity of PBMC supernatant</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nucleoside/nucleotide analogue-treated CHB patients</arm_group_label>
    <description>Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-naive CHB patients</arm_group_label>
    <description>Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese population: healthy volunteers, treatment naive CHB patients and nucleoside or&#xD;
        nucleotide analogue treated CHB patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All population:&#xD;
&#xD;
          -  Chinese population&#xD;
&#xD;
          -  Adequate hematological function: platelet count greater than or equal to (&gt;=) 100*10^9&#xD;
             per liter (/L), hemoglobin (Hb) &gt;= 12 grams/deciliter (g/dL) (male) or &gt;= 11 g/dL&#xD;
             (female), white blood cell (WBC) count &gt;= 4*10^9/L and &lt;= 11*10^9/L&#xD;
&#xD;
        Healthy volunteers:&#xD;
&#xD;
          -  Absence of evidence of any active or chronic disease&#xD;
&#xD;
          -  Negative hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis B surface&#xD;
             antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B envelope antigen&#xD;
             (HBeAg), hepatitis B envelope antiody (HBeAb) and hepatitis B core antibody (HBcAb)&#xD;
&#xD;
          -  Adequate liver function: transaminases alanine aminotransferase (ALT) &lt;= 1.0 times the&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
        Treatment naïve CHB patients:&#xD;
&#xD;
          -  HBsAg-positive (&gt;=250 international unit/milliliter [IU/mL]), compensated liver&#xD;
             function, non-cirrhotic&#xD;
&#xD;
          -  HBeAg-positive, HBV DNA &gt;= 200,000 IU/ml or equivalent copies/mL, ALT &gt;1.5 times the&#xD;
             ULN and ALT &lt;8 times the ULN&#xD;
&#xD;
        HBeAg-negative nucleoside/nucleotide analogue-treated CHB patients:&#xD;
&#xD;
          -  Subjects who HBeAg-seroconverted on nucleoside/nucleotide analogue therapy (treatment&#xD;
             for 1 to 3 years prior to enrollment) with HBV DNA &lt;90 IU/mL or below a detection&#xD;
             level acceptable by both the sponsor and investigator for at least the preceding 6&#xD;
             months; HBeAg negative and HBeAb positive&#xD;
&#xD;
          -  HBsAg-positive (&gt;=250 IU/mL), compensated liver function, non-cirrhotic -ALT &lt;= 1*ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of steroids or other immune suppressive agents within the last 4 weeks that would&#xD;
             impact the number/functions of white blood cells (WBC)&#xD;
&#xD;
          -  Any other diseases or clinical laboratory finding giving reasonable suspicion of a&#xD;
             disease or condition (including, but not limited to, cancer, lupus erythematosus,&#xD;
             rheumatoid arthritis, or other autoimmune disease) that could confound the result of&#xD;
             the study&#xD;
&#xD;
          -  Positive Hepatitis A immunoglobulin M (IgM) antibody, Hepatitis C antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) at screening&#xD;
&#xD;
          -  Significant acute infection, example; influenza, acute gastrointestinal symptoms or&#xD;
             any other clinically significant illness within 2 weeks&#xD;
&#xD;
          -  Previous/concurrent treatment with interferon-based therapy for CHB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

